This variability suggests that the phenotypic consequences of IDH1 mutations are not determined by the mutation in isolation but are instead shaped by the broader genomic and proteomic context, including the differences in expression of key glioma oncogenes and tumor suppressors that may modulate the impact of the 2OHG oncometabolite. Here, IDH1 is linked to central nervous system cancer.